S

ST Pharm Co Ltd
KOSDAQ:237690

Watchlist Manager
ST Pharm Co Ltd
KOSDAQ:237690
Watchlist
Price: 83 200 KRW -2.92% Market Closed
Market Cap: 1.7T KRW
Have any thoughts about
ST Pharm Co Ltd?
Write Note

ST Pharm Co Ltd
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

ST Pharm Co Ltd
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
S
ST Pharm Co Ltd
KOSDAQ:237690
Additional Paid In Capital
â‚©225.9B
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Additional Paid In Capital
â‚©6.5T
CAGR 3-Years
38%
CAGR 5-Years
21%
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Additional Paid In Capital
â‚©60.1B
CAGR 3-Years
28%
CAGR 5-Years
54%
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Additional Paid In Capital
â‚©120.7B
CAGR 3-Years
9%
CAGR 5-Years
32%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Additional Paid In Capital
â‚©97.5B
CAGR 3-Years
-34%
CAGR 5-Years
-12%
CAGR 10-Years
11%
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Additional Paid In Capital
â‚©170B
CAGR 3-Years
12%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

ST Pharm Co Ltd
Glance View

Market Cap
1.6T KRW
Industry
Life Sciences Tools & Services

ST Pharm Co., Ltd. develops and manufactures pharmaceutical products. The company is headquartered in Siheung, Gyeonggi-Do. The company went IPO on 2016-06-23. is a Korea-based company principally engaged in manufacture of pharmaceutical products. The firm's products mainly consist of generic active pharmaceutical ingredients (APIs), such as tipepidine hibenzate, doxifluridine, clopidogrel bisulfate, voriconazole and new medicine APIs, such as small molecule APIs. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
97 768.06 KRW
Undervaluation 15%
Intrinsic Value
Price
S

See Also

What is ST Pharm Co Ltd's Additional Paid In Capital?
Additional Paid In Capital
225.9B KRW

Based on the financial report for Sep 30, 2024, ST Pharm Co Ltd's Additional Paid In Capital amounts to 225.9B KRW.

What is ST Pharm Co Ltd's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
6%

Over the last year, the Additional Paid In Capital growth was 21%. The average annual Additional Paid In Capital growth rates for ST Pharm Co Ltd have been 10% over the past three years , 6% over the past five years .

Back to Top